Quantum Cyber N.V. current report, Q4 FY2024

Business Context and Reporting Period

This Form 6-K filing by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) covers the month of November 2024. The report details the results of an Extraordinary General Meeting of Shareholders held on November 13, 2024.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and shareholder voting results.

Material Changes

The primary material change reported is the shareholder approval to amend the Company's articles of association to effect a reverse stock split. This proposal was voted on and approved at the Extraordinary General Meeting.

Guidance, Outlook, and Risks

The filing contains no management commentary regarding financial guidance, future outlook, specific risks, or contingencies. It serves solely to disclose the outcome of the shareholder vote.

Important Facts for Investors

  • Shareholder Approval: All proposals at the Extraordinary General Meeting were approved.
  • Reverse Stock Split: Shareholders voted to authorize a reverse stock split via an amendment to the articles of association.
  • Voting Results: Of the 9,803,128 shares present (16.83% of outstanding shares), 8,262,897 votes were cast for the reverse stock split, 1,507,091 against, and 33,140 abstentions.
  • Record Date: The record date for the meeting was October 16, 2024.
  • Registration Impact: This report is incorporated by reference into the Company's Form F-3 and Form S-8 registration statements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.